These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24669768)

  • 21. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
    Yang H; Hui H; Wang Q; Li H; Zhao K; Zhou Y; Zhu Y; Wang X; You Q; Guo Q; Lu N
    Oncotarget; 2014 Sep; 5(18):8188-201. PubMed ID: 25149543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.
    Saliba J; Deleuze-Masquéfa C; Iskandarani A; El Eit R; Hmadi R; Mahon FX; Bazarbachi A; Bonnet PA; Nasr R
    Anticancer Drugs; 2014 Jul; 25(6):624-32. PubMed ID: 24463483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
    Ye YB; Lin JY; Chen Q; Liu F; Chen HJ; Li JY; Liu WQ; Garbay C; Vidal M
    Biochem Pharmacol; 2008 Jun; 75(11):2080-91. PubMed ID: 18455151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
    Klawitter J; Kominsky DJ; Brown JL; Klawitter J; Christians U; Leibfritz D; Melo JV; Eckhardt SG; Serkova NJ
    Br J Pharmacol; 2009 Sep; 158(2):588-600. PubMed ID: 19663881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
    Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
    Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; Corrêa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
    Baran Y; Oztekin C; Bassoy EY
    Cancer Invest; 2010 Jul; 28(6):623-8. PubMed ID: 20307198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
    Bernusso VA; Machado-Neto JA; Pericole FV; Vieira KP; Duarte AS; Traina F; Hansen MD; Olalla Saad ST; Barcellos KS
    Biochim Biophys Acta; 2015 Feb; 1853(2):388-95. PubMed ID: 25450971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells.
    Can G; Cakir Z; Kartal M; Gunduz U; Baran Y
    Anticancer Res; 2012 Jul; 32(7):2673-8. PubMed ID: 22753725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
    Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
    Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.